

Meeting of ICB Board

Date: Thursday 3rd October 2024

Time: 12.30 – 15.30

Location: Virtual, via Microsoft Teams

Agenda Number:	6.4
Title:	Review of updates to ICB Corporate Risk Register
Purpose: Approval	
Key Points for Discussion:	
<p>The ICB Corporate Risk Register (CRR) has been updated to reflect updates to our various Directorate Risk Registers.</p> <p>Risks scoring 15 or above are escalated to the CRR for approval by the ICB Board.</p> <p>The Audit and Risk Committee (ARC) reviewed the CRR at the meeting of 13th September and recommends to the ICB Board that they approve the content, accepting risks which have been escalated to the CRR and approving the closure or de-escalation of risks which have been resolved or have reduced.</p> <p>The Internal Audit into our Risk Management Assurance recommended that the ARC conduct regular 'Deep Dives' into areas of Risk. On discussion, the Committee agreed that the various Board Assurance Committees would be tasked to conduct Deep Dive reviews of the Directorate Risk Registers within their portfolios. These will be included in future Committee agendas, and relevant ICB managers invited to attend the discussions. It is proposed that the ICB Senior Leadership Team develop the programme of Deep Dives, informed by direction and guidance from the Assurance Committee members.</p>	
Recommendations:	<p>It is recommended that the ICB Board:</p> <ul style="list-style-type: none"> • Receive the attached CRR • Note the details • Accept the risks escalated to the CRR and approve the closure/de-escalation of risks from the CRR where indicated. • Note the approach to conducting Deep Dive reviews into Directorate Risk Registers by relevant Board Assurance Committees.
Previously Considered By and feedback :	<p>The CRR has been reviewed by the ICB SLT on 14/8/24 and again on 11/9/24, before being reviewed by the ARC on 13/9/24.</p> <p>The contributing Directorate Risk Registers have been reviewed by ICB Directors.</p>

Management of Declared Interest:	Not applicable
Risk and Assurance:	The management of our CRR is described in our Risk Management Framework. The recent Risk Management Assurance Internal Audit identified the requirement to include Deep Dive reviews at future Committee meetings
Financial / Resource Implications:	The CRR will be subject to ongoing review by ICB SLT in advance of future Committee meetings
Legal, Policy and Regulatory Requirements:	Advice on good practice in Risk Management is included in the HFMA Audit Committee Handbook
How does this reduce Health Inequalities:	No health inequalities issues arising as a result of this report, and there is no impact upon people with protected characteristics. Our Internal Auditors assist in advising on best practice in Population Health Management and Health Inequalities.
How does this impact on Equality & diversity	Our Risk Register can assist in identifying risks to Equality and Diversity, and in managing mitigating actions.
Patient and Public Involvement:	Not applicable to this report.
Communications and Engagement:	This report has not involved any external communications or engagement.
Author(s):	Nicole Saunders, Head of System Strategy and Planning
Sponsoring Director / Clinical Lead / Lay Member:	Sarah Truelove, Chief Finance Officer

Appendix 1: ICB Corporate Risk Register, updated to 26th September 2024

Risk ID/Regulatory Issue	Risk Title	Risk Description (Category, the risk itself, resulting in performance)	Reporting Method	Reporting Period	Responsible Party	Priority	Impact	Frequency	Current Status	Management actions already in place to mitigate risk (current controls)	Progression	Overall Status	Next Steps	Responsible Party	Reporting Period	Management actions already in place to mitigate risk (current controls)	Comments on progress	Reporting Period	Overall Status
ICS	000616	RISK SCORE HAS INCREASED AND IS NOW REPORTED ON CDR Provide certainty of the information relating to the non-clinical control register - rationale associated with COOC Risk we will not be compliant with the GMP track requirements as agreed with MHRA as this may result in breach warning and non-compliance	000616	27/06/2024	Shona Davitt	Jan Reid and Rob Wether	1	3	3	Review with the Chief Executive who is happy to accept the risk given the circumstances with the MOCC risk key staff out of the office	1	3	3	new risk	000616	Corporate Team reviewing and trying to complete missing information where they can			